Trevi Therapeutics (TRVI) Announces Proposed Public Offering of Common Stock, Warrants

September 22, 2022 4:01 PM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and the treatment of prurigo nodularis (PN), today announced that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof). All of the shares and pre-funded warrants are being offered by Trevi. In addition, Trevi expects to grant the underwriters a 30-day option to purchase shares of common stock equal to up to 15% of the number of securities sold in the public offering at the public offering price, less underwriting discounts and commissions.

SVB Securities, Stifel and Oppenheimer & Co. are acting as joint bookrunning managers for the offering. Needham & Company is acting as lead manager for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The shares and pre-funded warrants are being offered by Trevi pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission ("SEC") on June 26, 2020 and declared effective by the SEC on July 2, 2020.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Equity Offerings

Related Entities

Stifel, Needham & Company